Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
Status: Recruiting
Location: See all (14) locations...
Study Type: Observational
SUMMARY
This is a multi-centre, observational study, with retrospective data collection and prospective active follow-up. The aim is to measure the treatment pattern and real-world outcomes of EGFR-TKI as an adjuvant therapy in patients with early-stage EGFR-mutated NSCLC. The study period ranges from July 1st, 2022 to June 30th, 2031. Approximately 2,000 patients will be enrolled from 15 sites in China.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Diagnosed stage IB-III NSCLC on or prior to the index date;
• Initiated adjuvant EGFR-TKI from July 1st, 2023 to June 30th, 2026
Locations
Other Locations
China
Research Site
NOT_YET_RECRUITING
Beijing
Research Site
NOT_YET_RECRUITING
Chengdu
Research Site
NOT_YET_RECRUITING
Fuzhou
Research Site
NOT_YET_RECRUITING
Guangzhou
Research Site
RECRUITING
Guangzhou
Research Site
NOT_YET_RECRUITING
Nanchang
Research Site
NOT_YET_RECRUITING
Shanghai
Research Site
NOT_YET_RECRUITING
Shenyang
Research Site
NOT_YET_RECRUITING
Shijiazhuang
Research Site
NOT_YET_RECRUITING
Tianjin
Research Site
NOT_YET_RECRUITING
Wuhan
Research Site
NOT_YET_RECRUITING
Xi'an
Research Site
NOT_YET_RECRUITING
Xuzhou
Research Site
NOT_YET_RECRUITING
Zhengzhou
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2026-06-22
Estimated Completion Date: 2031-06-30
Participants
Target number of participants: 2000
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca